#United States #New York #Levi & Korsinsky #Cerevel Therapeutics #ABBV

Cerevel Therapeutics Holdings, Inc. Shareholder Alert

Attention shareholders of Cerevel Therapeutics Holdings, Inc.! If you invested in the company during the period from October 11, 2023, to August 1, 2024, it is crucial to consider your rights before June 3, 2025.

Levi & Korsinsky, LLP is reaching out to inform you about a class action securities lawsuit that is currently in progress. This case revolves around allegations of securities fraud that may have negatively impacted the value of your investment in Cerevel. The details surrounding this situation are alarming and merit your immediate attention.

Class Action Overview

The class action seeks to recover losses for investors who were affected by the alleged misconduct. Specifically, the lawsuit aims at individuals or entities that:
1. Sold or disposed of shares of Cerevel during the specified period.
2. Were holders of Cerevel stock on the record date of January 8, 2024, and had a right to vote on the merger with AbbVie Inc.
3. Sold shares at the same time that Bain Capital made its stock purchases on or about October 16, 2023.

The core of the complaint suggests that critical information was omitted regarding AbbVie's interest in acquiring Cerevel at a considerably higher price than the $22.81 per share offered during the secondary stock offering that took place on October 16, 2023. This lack of transparency may have artificially inflated prices until the merger details were disclosed.

Key Allegations

In particular, Bain Capital, Cerevel's controlling shareholder, purchased shares at a lower price during this controversial Offering while allegedly aware of AbbVie’s true acquisition intentions. When the acquisition was officially announced on December 6, 2023, Cerevel's stock skyrocketed to $45 per share, generating substantial gains for Bain on shares that it had purchased at artificially depressed prices.

Furthermore, Cerevel’s Proxy statement released on January 18, 2024, placed misconceptions about the timing and nature of AbbVie’s interest before the public, misleading shareholders and investors.

Next Steps for Shareholders

If you believe you qualify as a member of this class and suffered losses on your investment, time is of the essence. You must act by June 3, 2025, to request that the Court appoint you as lead plaintiff. Importantly, participating in this lawsuit does not necessitate acting as the lead plaintiff to benefit from any settlement or compensation that may arise.

No Financial Burden to Participate

If you are classified within the shareholder group, you might be eligible for compensation without incurring out-of-pocket expenses or fees. Levi & Korsinsky ensures that no cost or obligation exists for you to join this legal proceeding.

The Experience of Levi & Korsinsky

This firm has accumulated over 20 years of experience, recovering hundreds of millions for shareholders nationwide while maintaining a solid record in high-stakes litigation. Their team, comprising over 70 professionals, specializes in complicated securities litigation and has been consistently recognized as a top firm in this area.

Contact Information

If you have inquiries or wish to participate, please reach out to:

• - Joseph E. Levi, Esq.
• - Email: [email protected]
• - Phone: (212) 363-7500
• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

Don't miss this opportunity to understand your rights as a Cerevel Therapeutics shareholder and potentially recover your losses. Act promptly and make your voice heard!